Flemming Ørnskov

Flemming Ørnskov is the CEO of Galderma, a global dermatology company that has gained attention for its innovative biopharmaceuticals, including the recently approved therapeutic drug Nemluvio. Ørnskov has a strong background in the pharmaceutical industry, having previously held leadership roles at Shire, and is focused on successfully bringing new treatments to market while navigating the complexities of a rapidly evolving healthcare landscape.